5AM Ventures reposted this
This morning, Rallybio announced the initiation of dosing in a Phase 1 confirmatory PK/PD study evaluating RLYB116. Additionally, Rallybio announced that the initial indication focus for RLYB116 will be on two hematologic conditions with significant unmet need: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Patients suffering from these potentially life-threatening conditions have no approved or effective therapeutic options. Read our press release here: http://bit.ly/3SOTPjm
Congrats! Happy to see that RLYB116 is back in the clinic and wishing you all the best!
Go RallyBio team! Patients waiting for you extraordinary medicine
Driving advancements in vector biology & CAR-T therapies | Scientist dedicated to optimizing team performance | Expertise in molecular techniques & instrumentation
1moKeep going, Rallybio! Fight for patients!